Month: June 2023

The acquisition of Rebate Insight provides SpendMend with advanced rebate management automation tools to help healthcare organizations maximize rebate earnings and reduce supply costs.

…

The post SpendMend Acquires Rebate Insight to Expand Suite of Healthcare Cost-Cycle Optimization Solutions first appeared on Enrose Magazine.

TAMPA, Fla., June 6, 2023 (Newswire.com)
–
Oncology informatics company Inspirata recently reached out to several hundred customer sites with an invitation to participate in a Customer Satisfaction survey. The company collected more than 60 responses, representing healthcare organizations varying in size, geography, and the Inspirata product they have been using. 

The survey results reveal a strikingly high percentage of Inspirata customers (92%) who express strong overall satisfaction. Putting this in terms of a well-understood and standardized metric, the company’s net promoter score (NPS) stands at 56, which places Inspirata in the 100^th percentile of the software industry, according to benchmarks on Delighted.com (a website run by Qualtrics, an industry-leader in market research technology). 

“We are delighted to see such a level of enthusiasm among our customers as we recognize how high an NPS of 56 compares to mainstay brands in healthcare technology. According to recent publicly available data, IQVIA has an NPS of 28, while Epic’s NPS is 30. It is very exciting to see Inspirata comparing favorably against some of the largest players in the industry,” said Emil Mladenov, VP of Marketing and Strategic Partnerships at Inspirata.

The high ratings can be attributed to customers’ strong appreciation of both Inspirata’s products and the support the Inspirata team is providing when needed.

On the product side, customers report their teams are experiencing average productivity gains between 45% and 50% from using Inspirata products. Nine out of 10 customers are satisfied with product stability.

“Inspirata’s products are deeply rooted in AI and NLP technology that the company has been developing in collaboration with the NCI’s SEER program and hundreds of healthcare institutions over two decades. Many other vendors offering AI or NLP still struggle with accuracy and reliability. This is why we are extremely proud to see less than 2% of our customers expressing concerns with the accuracy of our technology. Knowing that our existing customers are getting the results they expect gives us strong confidence when we speak to new customers,” said Jesse Turner, VP of Sales at Inspirata.

“While very much pleased to see these results, my team and I are not surprised that customers recognize the accuracy and stability of our technology,” said George Cernile, VP of AI and NLP Technology at Inspirata. “These results align closely with the Quality Control (QC) studies that we periodically do with our customers. For example, since the beginning of 2020, over more than 40 QC studies, we see sensitivity of 99% and specificity of 98%, with very little variation – only within several percentage points – across the various sites where our products are installed. That demonstrates successfully scaling the technology across different systems and physicians, which can be a significant challenge for most AI and NLP solutions.”

On the customer support side, 96% of customers who had needed help are satisfied with the services provided by the Inspirata team. This is further evidenced by extremely positive quotes provided by survey respondents, such as the following two examples:

• “I love the level of customer service that Inspirata provides.” – A verbatim quote from a user at a Georgia-based medical center.
• “The customer service has been top notch every time I have needed to contact them.” – a verbatim quote from a user at a university hospital in New Jersey.

“We strive for excellence in every single interaction we have with our customers,” said Laure Tessier-Delivuk, VP of Operations at Inspirata. “What we see in the Customer Satisfaction survey correlates very well with the feedback we collect after closing every single support ticket. Over the past two years, we’ve maintained a 4.9 out of 5 for overall level of satisfaction related to how we handle customer requests.”

Inspirata has also leveraged the data from the Customer Satisfaction survey to learn about potential product areas for improvement or identify unaddressed customer needs. The company is confident that drawing up action plans to incorporate as many of customers’ suggestions as possible would make the next generation of products even more impactful and easier to use.

“The survey gives us access to very interesting data. The good news is that for every feature request made in the survey, we have already managed to add a user story to our product roadmap. Many of these new features or functionalities are on track to be delivered before the end of the year,” said Tim Masters, Director of Product Management and Design. 

To learn more about the company, its portfolio of solutions, the decades of work dedicated to refining its AI and NLP technology for clinical data use cases, and the team behind all this, please visit Inspirata.com.

About Inspirata

Inspirata, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. We are an oncology informatics company that offers several innovative software solutions leveraging scalable AI and NLP in the clinical trial and cancer registry spaces. Refined over two decades in collaboration with the National Cancer Institute (NCI) and used by hundreds of healthcare institutions globally, our proprietary NLP engine is at the heart of Trial Navigator, our growing suite of fully automated clinical trial matching solutions, and E-Path Plus, our industry-leading cancer registry reporting and data abstraction solution. 

Contact Information:

Emil Mladenov

Vice President of Marketing and Strategic Partnerships

[email protected]

+1 813-570-8914

Original Source:

A Recent Survey Reveals That Customers Love Interacting With Inspirata’s Products and Team

The post A Recent Survey Reveals That Customers Love Interacting With Inspirata’s Products and Team first appeared on Enrose Magazine.

Communication is the cornerstone of quality healthcare, making effective communication critical to quality outcomes for patients with communication barriers.

ANN ARBOR, Mich., June 6, 2023 (Newswire.com)
–
Released today, VidaTalk expands its impact, further empowering the most vulnerable patients throughout the healthcare system with its new talk-to-text feature. By providing seamless communication between patients who are hard of hearing and their healthcare professionals, VidaTalk ensures these patients are able to comprehend medical information accurately and effectively.

“Empowering autonomy for patients with speech and language barriers is our core mission,” states Dr. Patak, CEO of Vidatak, LLC. “Our Program is unique in that our active, ongoing engagement with our clients allow us to capture best practices from world class healthcare systems across the country and share these with our clients to help optimize their workflow processes and provider education in a way that achieves the patient empowerment and autonomy they envision was possible.” 

VidaTalk is not just a solution; it is a change in practice. 

To use the talk-to-text feature, simply tap on the keyboard tab, then activate the microphone by tapping on the microphone symbol. All transcription is performed in real time. No data is stored.

Lisa Spencer, Vidatak’s Chief Experience Officer shares her insight explaining, “VidaTalk promotes equitable and patient-centered healthcare experiences for patients who rely on sign language interpreters, and even more importantly, for those patients who lost their hearing and haven’t learned signed language.”

Talk-to-text has transformed the way healthcare providers engage with their patients who are hard of hearing, improving efficiency, accuracy, mutual understanding and comprehension of care, fostering independence and enhancing relationships. 

Healthcare institutions that embrace and implement such advancements to ensure inclusive and accessible care for their most vulnerable patients – including those with speech, hearing and language barriers – model health equity and are positioned to report the best outcomes and be the most profitable.

Contact Information:

Lance Patak

CEO

[email protected]

(323) 697-9906

Lisa Spencer

Chief Experience Officer

[email protected]

‭(425) 247-4007‬

Related Images

Original Source:

Vidatak Adds Transformative Talk-to-Text Captioning Feature to Multi-Lingual Patient Communication Application, VidaTalk

The post Vidatak Adds Transformative Talk-to-Text Captioning Feature to Multi-Lingual Patient Communication Application, VidaTalk first appeared on Enrose Magazine.

Sustained acoustic medicine delivered by wearable ultrasound device and topical diclofenac patch reduced patients’ pain and improved clinical outcomes beyond traditional patient care.

TRUMBULL, Conn., June 5, 2023 (Newswire.com)
–
A new clinical study in the January Global Journal of Orthopedics Research shows that, for those who saw no improvement from physical therapy alone, ZetrOZ Systems‘ sustained acoustic medicine device (sam®), in combination with common topical diclofenac, reduces pain and restores health in patients with acute and chronic injuries to the shoulder, elbow, leg, and foot.

The study examined the results of long-duration sonophoresis (LDS) and the use of ultrasound to enhance the movement of medications into tissue, involving 135 patients at Yale-New Haven Health System and Sport and Orthopaedic Physical Therapy in Connecticut undergoing physical therapy for a variety of acute and chronic injuries and whose pain did not respond to physical therapy for four weeks or more.

Researchers found that patients in all age groups reported their pain decreased significantly and they felt healthier and more capable.  

“Both the clinical research and daily patient real-world outcomes demonstrate that sam® helps people heal faster and improve the quality of their everyday lives,” said Dr. George Lewis, founder and CEO of ZetrOZ. “This new research shows another way that sam® with topical diclofenac can improve treatment for soft tissue injuries and other conditions, by activating healing for multiple hours each day.” 

The new study involved sam® treatment in combination with the medication diclofenac, which together reduces inflammation and pain and is used to treat injuries to joints, muscles, and bones. Typically diclofenac can be taken orally or applied topically, but both methods can be problematic. Long-term use of oral diclofenac sodium can lead to gastrointestinal bleeding and other adverse effects while the effectiveness of topical diclofenac cream is limited because of the messy application and limited absorption.  

However, recent studies have shown that using topical diclofenac in combination with continuous ultrasound can significantly increase its efficacy. The new study bears that out.  

ZetrOZ’s sam® is a wearable ultrasound device that delivers continuous therapy for up to four hours. The long-duration ultrasound activates cellular proliferation and generates deep heat, convection, and vasodilation, which “potentially enhances the localized drug delivery,” the researchers said. 

In the study, the sam® device with 2.5% diclofenac was applied to the shoulder, elbow, lower hamstring, and plantar fascia of the patients. The patients reported that the device was easy to use at home, and 100% of patients said they would be willing to keep using the device.  

In addition, 98.5% of patients reported that the long-duration ultrasound improved musculoskeletal injury care. Before the study, patients reported an average pain score of 6.88 on a 10-point scale, indicating moderate to severe pain. After the treatment, patients reported that most of their pain had been eliminated, with a 4.44-point reduction to the original score.  

Patients also were asked to assess how much their health had changed, on a scale of -7 (“a very great deal worse”) to 7 (“a very great deal better”). The average response was 4.85, indicating the patients perceived a significant health improvement.  

Patients of all ages reported improved pain and health, with younger patients reporting the greatest benefits. The degree of improvement varied by type of injury but was positive and significant across all injuries, the researchers found. 

“LDS may be easily integrated into patient care to reduce the pain and accelerate the healing process,” the researchers concluded. The study had a high treatment satisfaction rate, showing the ease of use of the at-home treatment option for patients. 

ZetrOZ Systems’ sam® technology was developed in part with funding from the National Institute of Health, National Science Foundation, Department of Defense, and NASA. ZetrOZ Systems products are designed and manufactured in the United States and are protected by 46 U.S. patents.  

To learn more, visit www.samrecover.com. 

About ZetrOZ Systems 

ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of +46 patents and is the exclusive manufacturer and developer of the sam® product line, which is designed for the treatment of acute and chronic musculoskeletal conditions. 

Contact Information:

Maria Penaloza

[email protected]

Original Source:

New Study Shows ZetrOZ Systems’ sam Technology Rapidly Rehabilitates Musculoskeletal Injuries at Home

The post New Study Shows ZetrOZ Systems’ sam Technology Rapidly Rehabilitates Musculoskeletal Injuries at Home first appeared on Enrose Magazine.